Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib plus anastrozole in Japanese patients with HR-positive, HER2-negative metastatic or recurrent breast cancer
jRCT2041250084Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ribociclib in breast cancer (2 arms), sponsored by Novartis. Primary endpoints: Tolerability (Phase Ib) and Overall response rate (ORR) by central review (Phase II). Started Nov 2025; status: active, not recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2041250084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041250084.